CVS Health stock holds in the mid-$90s as analysts highlight turnaround potential
Published on 08/27/2026 at 15:08 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
CVS Health Corp. (ISIN US1266501006) stock is trading in the mid-$90 range as of August 27, 2026, with recent market data showing the shares closing at $94.32 on August 26, 2026 and an intraday quote around $94.28 the following day.
Recent coverage points to a moderate buy consensus and a forward price-to-earnings ratio near 12, framing CVS Health as a turnaround candidate where valuation and earnings trends now sit at the center of the investor debate.
The company is also seeing tangible demand in newer areas such as Medicare-backed obesity drug programs, giving investors additional data points on how CVS Health’s integrated model may translate into future growth.
Analyst view and valuation backdrop
One recent earnings and valuation overview notes that CVS Health closed at $94.32 on August 26, 2026, with a trailing price-to-earnings ratio of 25 and a forward price-to-earnings ratio of 12, alongside a beta of 0.596 that points to lower volatility versus the broader market.
That same overview places a narrative fair value estimate at $114.88 per share, implying upside of just over $20 per share from the late-August trading level, and reinforcing the picture of CVS Health as a company where investors are paying forward for earnings compounding tied to its integrated healthcare strategy.
Another market snapshot describes CVS Health’s trailing total returns as of August 26, 2026, with the stock price quoted at $94.28 during trading on August 26, 2026, up around 1.48 percent on the day, a move that sits against concerns that revenue growth has slowed even as management emphasizes strength in the GLP-1 drug market.
In addition, a rating summary from the same coverage set states that CVS Health currently carries a consensus rating of “Moderate Buy” and a consensus target price of $107.17, which stands more than $12 per share above the $94.22–$94.32 price band reported in late August 2026.
From a risk-reward perspective, the valuation context is specific: a trailing price-to-earnings ratio more than double the forward multiple suggests that the market expects earnings growth to accelerate, while still pricing in regulatory and reimbursement uncertainty in pharmacy and health insurance operations.
Fresh commentary on CVS Health stock
Additional commentary on August 27, 2026 highlights that shares of CVS Health opened at $94.22 in the latest session, consistent with the prior close reported at $94.32, and that investors continue to frame the stock as a turnaround story where execution on pharmacy benefit management and insurance margins will determine whether the fair value narrative plays out.
Another article on the same date characterizes CVS Health as reshaping its board while the stock trades at $94.32 against that fair value marker of $114.88, underscoring that governance and strategy adjustments are being made while the market still prices in a discount of more than 18 percent versus the modeled fair value.
The commentary also situates CVS Health within the broader universe of income and retirement portfolios, noting that the shares’ lower beta and forward valuation make the stock a candidate for investors who are balancing dividend income and exposure to healthcare demand, though the company must show that its integrated model can deliver consistent earnings growth.
In this context, the quantified spread between the late-August share price and the consensus and fair value estimates is central: with the consensus target price at $107.17 and fair value around $114.88, the discount ranges between roughly $13 and over $20 per share versus current trading levels in the mid-$90s.
For investors, the question is less whether CVS Health stock is cheap on simple multiples and more whether near-term earnings and cash flows can justify the implied re-rating, especially at a time when pharmacy margins, drug pricing dynamics, and health-plan utilization trends are in flux.
Operational context and GLP-1 demand
Operationally, CVS Health is seeing notable volume in obesity drug prescriptions tied to new Medicare programs, with one report indicating that CVS has already filled more than 100,000 “Bridge” prescriptions for GLP-1 obesity treatments as of mid-August 2026.
That figure represents a concrete proof point for demand in this category and highlights how quickly patients are moving to take advantage of a Medicare program that caps cost at $50 per month, a trend that could influence both pharmacy traffic and pharmacy benefit management economics.
The same reporting notes that CVS and other chains have each filled around 100,000 prescriptions under these programs within less than two months, indicating a rapid ramp-up in volumes that will feed into upcoming quarters’ revenue and margin metrics in the pharmacy and PBM segments.
For CVS Health, this surge in GLP-1 prescription activity sits alongside a broader narrative in which analysts acknowledge strong recent quarterly results while still voicing caution that revenue growth may be decelerating; this mix of strong segment performance and top-line concerns explains why the consensus rating has settled at “Moderate Buy” rather than a more aggressively positive stance.
Looking forward, investors will watch whether the heavy prescription volumes translate into sustainable margin contributions, particularly in light of rebate structures and changing price dynamics for GLP-1 therapies and other chronic-disease drugs.
Board changes and turnaround framing
Corporate governance is part of the turnaround story, with recent analysis pointing out that CVS Health is reshaping its board of directors while the share price trades below internal and external fair value estimates, suggesting that management and directors are trying to align oversight and strategic direction with the company’s evolution into an integrated healthcare platform.
Those board-level changes come at a time when CVS Health’s business model spans retail pharmacies, pharmacy benefit management, health insurance through Aetna, and care delivery via minute clinics and other sites, making board expertise in both traditional healthcare and data-driven care management important for long-term execution.
The idea of CVS Health as a bargain is explicitly framed against the fair value estimate of $114.88 and the current $94.32 price, with analysts arguing that if the company can continue to compound earnings across its segments, the discount should narrow over time.
However, concerns remain around reimbursement pressure, competitive dynamics with other integrated players, and the challenge of managing a business that is simultaneously a dominant pharmacy chain, a pharmacy benefit manager, and a health insurer; the board reshaping is therefore viewed as both a response to this complexity and an effort to strengthen oversight.
Investors watching CVS Health stock in late August 2026 are thus weighing strategic changes alongside hard valuation metrics, and the stock’s behavior around the mid-$90s price band provides a real-time indicator of how the market is digesting these signals.
Representative product: MinuteClinics as part of care delivery
One tangible example of CVS Health’s integrated approach is its network of walk-in care sites branded as clinics located inside or adjacent to many of its retail pharmacy stores, which provide basic primary care, preventive services, and chronic-condition management in a lower-cost, highly accessible setting.
These clinics are designed to expand access for patients who may not have a regular physician or who need care outside traditional office hours, and they link directly into CVS Health’s pharmacy and insurance infrastructure, enabling coordinated prescription fulfillment and benefits processing.
From an investor standpoint, the clinics serve as a product-like feature of the business that can drive incremental foot traffic, prescription volume, and engagement with CVS Health’s insurance offerings, reinforcing the integrated model that underpins the company’s long-term narrative.
As obesity treatments, chronic-disease drugs, and preventive-care programs become more central to healthcare strategies, these clinics could play an important role in managing patient journeys, supporting adherence, and capturing data that informs both pharmacy operations and insurance risk management.
CVS Health stock level and late-August snapshot
At the latest snapshot for late August 2026, CVS Health stock is quoted in multiple market-data overviews in the $94.22 to $94.32 range, with one real-time feed showing an intraday price of $94.28 as of August 26, 2026 and another noting that shares opened at $94.22 in the following session.
The latest price-feed page also shows CVS Health stock at $94.32 with a daily change of $1.42, equivalent to a gain of 1.53 percent on that session, underscoring that the shares have recently moved higher within their current trading band.
While detailed 52-week range or market-cap figures are not fully specified in the immediate coverage, the available data on price, daily percentage moves, and valuation ratios provide investors with a coherent picture of CVS Health’s late-August 2026 positioning: a mid-$90 share price, trailing price-to-earnings ratio of 25, forward price-to-earnings ratio of 12, and a discount of more than $12 per share versus the consensus target price of $107.17.
For investors tracking CVS Health stock, the combination of mid-$90 trading levels, moderate buy consensus, and strong GLP-1 prescription volumes leaves the stock squarely in the category of a healthcare turnaround where execution over the next few quarters will determine whether the valuation gap closes.
Read more
Further earnings and valuation context for CVS Health
Company snapshot
Company: CVS Health Corp.
ISIN: US1266501006
Ticker: CVS
Exchange: NYSE
Sector / Industry: Health care - diversified healthcare services and retail pharmacies
